Clinical Trial Update: Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing adalimumab and tofacitinib for active Takayasu arteritis is being conducted; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Takayasu Arteritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Chinese SLE Treatment And Research Group | Conditions: Takayasu Arteritis | Phase 4 | Status: UNKNOWN